Abstract:In the published manuscript, "Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation. Yinggang Hua, Yanling Liu, Long Li and Guoyan Liu, Open Life Sciences. 2023;18(1): 20220078. https://doi.org/10.1515/biol-2022-0078," the authors have found an unintentional error made during preparation of Figure 2. The statement from the authors reads as follows: During our recent review of the experiments described in the article, we identified an issue. Specifically, in Figure 2 of the article, there is an error in the Western blot (WB) images of P-c-Jun and c-Jun. This error occurred during the figure preparation process, where the WB images of P-ERK1/2 and ERK1/2 were mistakenly placed in the positions for P-c-Jun and c-Jun, resulting in repeated images. Figure 1 in this letter highlights the erroneous information. Red box indicates the repeated images of P-c-Jun and c-Jun in Figure 2 of the article. Figure 2 presents the actual WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). (a and b) The WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). Our experimental results indicate that the protein level of P-c-Jun increases after stimulation of SGC-7901 cells with MRS2365 (agonist), suggesting the phosphorylation and activation of c-Jun in the signaling pathway. Based on these accurate and reliable experimental results, we have created a new version of Figure 2 from the original manuscript. The new Figure 2 (here as Figure 3) corrects the WB results for P-c-Jun and c-Jun (MRS2365 agonist and MRS2500 antagonist). The corrected image does not affect the core content and conclusions of the original paper. Corrected version of Figure 2 in the article. The authors admit the error and claim that this is an unintentional error that has nothing to do with academic misconduct and does not influence the conclusion of the publication. The authors apologize to the editor, the staffs of the journal, and the journal readers for the mistake and any inconvenience it caused. # These authors contributed equally to this work. © 2024 the author(s), published by De Gruyter This work is licensed under the Creative Commons Attribution 4.0 International License.

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Correction: Corrigendum: Lysine Acetylation and Succinylation in HeLa Cells and Their Essential Roles in Response to UV-induced Stress

Correction: Corrigendum: A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation

Correction: Chao Et Al. MicroRNA-22-3p and MicroRNA-149-5p Inhibit Human Hepatocellular Carcinoma Cell Growth and Metastasis Properties by Regulating Methylenetetrahydrofolate Reductase. Curr. Issues Mol. Biol. 2022, 44, 952–962

Erratum to "Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation"

Erratum: Synergism from the Combination of Ulinastatin and Curcumin Offers Greater Inhibition against Colorectal Cancer Liver Metastases via Modulating Matrix Metalloproteinase-9 and E-Cadherin Expression [Corrigendum]

Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC

Correction: Cui, H., et al. BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation. Int. J. Mol. Sci. 2019, 20, 4062

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

[Corrigendum] Effect of STC2 gene silencing on colorectal cancer cells

Corrigendum to "Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology" [ Cancer Pathog Ther. 2024;2:205-211]

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]